The transcriptional regulator gene ARID5B, which was more frequently mutated among the slow responders to induction therapy (proportion of slow vs. fast responders carrying a mutation: 0.059 vs. 0.01 based on mid-induction MRD, p < 0.05; 0.029 vs. 0.01 based on EOI MRD p < 0.1), consistent with previous reports linking it to poor treatment outcome in ALL [46]. This evidence concerns the gene ARID5B and acute lymphoblastic leukemia.